Right Brain Bio Partners with Suven Pharmaceuticals to Develop New Parkinson's Disease Drug

In a pivotal development for the treatment of Parkinson's disease, Right Brain Bio, a biotechnology company focused on innovative treatments for complex illnesses, has announced a manufacturing agreement with Suven Pharmaceuticals. This collaboration aims to produce RB-190, a groundbreaking drug designed to address the root causes of Parkinson's disease rather than just alleviate symptoms. This agreement comes at a critical time as the prevalence of Parkinson's is projected to increase significantly in the coming years, necessitating new and effective treatment options.

Parkinson's disease, which affects over 1 million Americans, ranks as the second most common neurodegenerative disorder, following Alzheimer's. With an aging population, it is anticipated that cases will double by the year 2030. This alarming trend underscores the urgent need for innovative therapies like RB-190.

RB-190 is not just another symptom management solution; it represents a transformative approach in the fight against Parkinson's disease. This drug is a repurposed form of metyrosine and is backed by research conducted by Dr. Jonathan Sackner-Bernstein, the Founder and CEO of Right Brain Bio. His studies have indicated that excessive exposure to dopamine can lead to neurotoxicity, which is a significant factor driving the progression of Parkinson's disease. Preclinical studies conducted across nine different models have demonstrated that RB-190 has the potential to reverse the pathological processes associated with this debilitating condition.

At the announcement of this partnership, Dr. Sackner-Bernstein expressed enthusiasm regarding the journey towards clinical trials. He stated, “We are excited to collaborate with Suven Pharma as we move RB-190 toward clinical trials. Bringing a novel therapy to clinical trials requires manufacturing excellence and stringent regulatory compliance. With Suven's expertise, cutting-edge facilities, and recent successful FDA review, we are confident in delivering RB-190 at the highest quality standards for our upcoming trials.”

Suven Pharmaceuticals is a technology-driven global Contract Development and Manufacturing Organization (CDMO) known for its commitment to quality in drug manufacturing. Vivek Sharma, the Executive Chairman of Suven, shared his excitement about contributing to this innovative therapy’s development. He emphasized that Suven’s extensive experience and regulatory knowledge will help ensure that RB-190 meets global quality standards during its production. Sharma added, “The potential of RB-190 to redefine Parkinson's treatment is truly inspiring, and we are proud to contribute our expertise in drug manufacturing to support its development.”

With over three decades of experience and a workforce exceeding 1,000 employees across India and New Jersey, Suven has built a solid reputation as a trusted partner in contract drug development and manufacturing. The company has completed over 1,000 projects and operates facilities that have been audited by the US FDA to meet the highest industry standards.

About Right Brain Bio: Founded in 2018, Right Brain Bio has adopted a unique approach using its proprietary